Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial | Zendy

Antonio Cuadrado | Zendy; José R. Salcines-Caviedes | Zendy; Miguel F. Carrascosa | Zendy; Trinidad DierssenSotos | Zendy; M. Cobo | Zendy; Mônica Rodrigues Campos | Zendy; B. Ayestaran | Zendy; A. Fernandez-Pousa | Zendy; E González-Colominas | Zendy; S. Aresti-Zarate | Zendy; Marcela Hernández | Zendy; Ethan Pascual | Zendy

Open Access

Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial

Author(s) -

Antonio Cuadrado,

José R. Salcines-Caviedes,

Miguel F. Carrascosa,

Trinidad DierssenSotos,

M. Cobo,

Mônica Rodrigues Campos,

B. Ayestaran,

A. Fernandez-Pousa,

E González-Colominas,

S. Aresti-Zarate,

Marcela Hernández,

Ethan Pascual

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks209

Subject(s) - clarithromycin , levofloxacin , medicine , helicobacter pylori , regimen , randomized controlled trial , gastroenterology , antibiotics , microbiology and biotechnology , biology

There is growing evidence that the standard triple therapy against Helicobacter pylori infection is losing clinical effectiveness. A triple therapy regimen with levofloxacin, amoxicillin and a proton pump inhibitor has been reported to be effective and well tolerated, and this regimen has been suggested as an alternative first-line treatment. The aim of this single-blind randomized clinical trial was to compare the eradication success of two first-line triple therapy regimens in the north of Spain: clarithromycin, amoxicillin and omeprazole (CAO) versus levofloxacin, amoxicillin and omeprazole (LAO).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research